Could a chemo combo save lungs in scleroderma patients?
NCT ID NCT01570764
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a combination of the chemotherapy drug cyclophosphamide and the steroid prednisone could help people with scleroderma-related lung disease. Forty adults whose lung function had worsened in the past year received either the drug combo or a placebo plus prednisone for 12 months. The goal was to see if the treatment could stabilize or improve lung volume and gas exchange.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide (chemotherapy drug) plus prednisone (steroid)
- What this could lead to
- If it works, this could offer a way to slow or stop lung decline in people with scleroderma-related lung disease.
- What could go wrong
- This is a small, completed phase 3 trial with only 40 participants. Cyclophosphamide can have serious side effects, and the benefit may not be large or lasting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cochin Hospital
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a skin patch ease stomach pain in scleroderma?
- Can AI catch lung scarring that doctors might miss?
- Can arm workouts boost oxygen use in lung disease?
- Immune clues in the blood may foretell heart trouble
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- Blood particles may reveal hidden clues to scleroderma complications